Navigation
Navigation

Capricorn Health-tech Fund

The Capricorn Health-tech Fund (CHF) focuses on human health-technology investments. Health-technologies relate to the prevention, the diagnosis and the treatment of diseases.

Sequana Medical announces first-in-human data of Direct Sodium Removal (DSR) therapy published in Circulation

News
- 10/01/2020
Positive pre-clinical and clinical proof-of-concept data of Sequana Medical’s innovative DSR therapy published in top tier peer-reviewed cardiovascular journal Data demonstrates potential for treatment of volume overload due to heart failure Ghent, Belgium: 10 January…
Read more

Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients

News
- 07/01/2020
The study aims to: Evaluate the safety of alfapump DSR in patients with heart failure Assess the feasibility of alfapump DSR to remove excess sodium and fluid from the body Explore the potential impact of…
Read more

Team
Dr Jos B. Peeters
Chairman of the Executive Committee - Responsible for venture capital, finance and IT
Dr Katya Smirnyagina
Executive Director Capricorn Health-tech Fund

Portfolio

Success stories

Ogeda

Ogeda [Belgium] is a drug development company with a chemistry service business focusing on discovery of small molecules targeting GPCRs.